KATHLEEN MAHONY: Open Payments
NPI 1023124294 · RIVERSIDE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,389 in 11 payments from 11 companies in 2025. Trend: 2023 $1,737 · 2024 $841 · 2025 $1,389
Food & beverage: $1,389
| Company | Payments | Amount |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 1 | $150 |
| Amgen Inc. | 1 | $143 |
| Neurocrine BioSciences, Inc. | 1 | $131 |
| Regeneron Healthcare Solutions, Inc. | 1 | $126 |
| Apellis Pharmaceuticals, Inc. | 1 | $125 |
| ABBVIE INC. | 1 | $125 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Alkermes, Inc. | 1 | $125 |
| Novo Nordisk Inc | 1 | $122 |
| PFIZER INC. | 1 | $110 |
Products named: DUPIXENT, KRYSTEXXA, CRENESSITY, Syfovre, AVYCAZ, Auvelity, LYBALVI, Ozempic.
Industry payments across CA — which companies pay providers there.
